The DOI matches its Crossref record; 97 of the 97 references it cites were found in a registry or an index.
Antipsychotic-associated weight gain: management strategies and impact on treatment adherence
Open accessAbstract
Antipsychotic-induced weight gain is a major management problem for clinicians. It has been shown that weight gain and obesity lead to increased cardiovascular and cerebrovascular morbidity and mortality, reduced quality of life and poor drug compliance. This narrative review discusses the propensity of various antipsychotics to cause weight gain, the pharmacologic and nonpharmacologic interventions available to counteract this effect and its impact on adherence. Most antipsychotics cause weight gain. The risk appears to be highest with olanzapine and clozapine. Weight increases rapidly in the initial period after starting antipsychotics. Patients continue to gain weight in the long term. Children appear to be particularly vulnerable to antipsychotic-induced weight gain. Tailoring antipsychotics according to the needs of the individual and close monitoring of weight and other metabolic parameters are the best preventive strategies at the outset. Switching to an agent with lesser tendency to cause weight gain is an option, but carries the risk of relapse of the illness. Nonpharmacologic interventions of dietary counseling, exercise programs and cognitive and behavioral strategies appear to be equally effective in individual and group therapy formats. Both nonpharmacologic prevention and intervention strategies have shown modest effects on weight. Multiple compounds have been investigated as add-on medications to cause weight loss. Metformin has the best evidence in this respect. Burden of side effects needs to be considered when prescribing weight loss medications. There is no strong evidence to recommend routine prescription of add-on medication for weight reduction. Heterogeneity of study methodologies and other confounders such as lifestyle, genetic and illness factors make interpretation of data difficult.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
Role of AMP-Activated Protein Kinase in Mechanism of Metformin Action
Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13505 · Cited by 5,652 · cited 1×
“It exerts its action by inhibiting hepatic gluconeogenesis and improving the sensitivity of insulin in skeletal muscles via adenosine monophosphate kinase.(58) It also reduces low-density lipoprotein cholesterol and triglycerides.”
BackgroundLeucht, S., Cipriani, A., Spineli, L., Mavridis, D., Örey, D., Richter, F., Samara, M., Barbui, C., Engel, R. R., Geddes, J. R., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60733-3 · Cited by 2,561 · cited 4×
“This study replicated the findings of Leucht et al.(10) Table 1 ranks the antipsychotics according to the likelihood of causing weight gain, considering the current evidence.”
BackgroundMethodResultInfluentialAntipsychotic-induced weight gain: a comprehensive research synthesis
Allison, D. B., Mentore, J. L., Heo, M., Chandler, L. P., Cappelleri, J. C., Infante, M. C., & Weiden, P. J. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.11.1686 · Cited by 2,382
Metabolic Syndrome and Risk of Incident Cardiovascular Events and Death
Gami, A. S., Witt, B. J., Howard, D. E., Erwin, P. J., Gami, L. A., Somers, V. K., & Montori, V. M. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.09.032 · Cited by 1,888
Risperidone in Children with Autism and Serious Behavioral Problems
McCracken, J. T., McGough, J., Shah, B., Cronin, P., Hong, D., Aman, M. G., Arnold, L. E., Lindsay, R., Nash, P., Hollway, J., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa013171 · Cited by 1,574 · cited 1×
“Peer perception too plays a significant role.(31) Changes in the physical appearance can lead to body image issues and problems with self-esteem, which in turn could lead to poor compliance with medication.”
BackgroundPi-Sunyer, F. X., Aronne, L. J., Heshmati, H. M., Devin, J., Rosenstock, J., & RIO-North America Study Group, F. T. (2006) · JAMA · doi:10.1001/jama.295.7.761 · Cited by 1,218
Metabolic and cardiovascular adverse effects associated with antipsychotic drugs.
De Hert, M., Detraux, J., van Winkel, R., Yu, W., & Correll, C. U. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.156 · Cited by 1,145 · cited 1×
“In addition to weight gain, antipsychotics are also known to impair glucose metabolism, increase cholesterol and triglyceride levels and cause arterial hypertension, leading to metabolic syndrome.(1) Metabolic syndrome will increase the risk of diabetes mellitus by five times and cardiovascular illness by two times ov…”
BackgroundPremature Mortality Among Adults With Schizophrenia in the United States
Olfson, M., Gerhard, T., Huang, C., Crystal, S., & Stroup, T. S. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2015.1737 · Cited by 1,083
Mitchell, A. J., Vancampfort, D., Sweers, K., van Winkel, R., Yu, W., & De Hert, M. (2013) · Schizophrenia Bulletin · doi:10.1093/schbul/sbr148 · Cited by 1,082
Correll, C. U. (2009) · JAMA · doi:10.1001/jama.2009.1549 · Cited by 1,050 · cited 2×
“Correll et al argued that weight gain was more in the young due to less prior antipsychotic exposure compared to adults.(24) Weight gain in the young is more than in adult patients with first episode or chronic schizophrenia.”
BackgroundVilsboll, T., Christensen, M., Junker, A. E., Knop, F. K., & Gluud, L. L. (2012) · BMJ · doi:10.1136/bmj.d7771 · Cited by 970
Rummel-Kluge, C., Komossa, K., Schwarz, S., Hunger, H., Schmid, F., Lobos, C. A., Kissling, W., Davis, J. M., & Leucht, S. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.07.012 · Cited by 675
Velligan, D. I., Weiden, P. J., Sajatovic, M., Scott, J. L., Carpenter, D., Ross, R., & Docherty, J. P. (2009) · PubMed · Cited by 625
Lieberman, J. A. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.0207e04 · Cited by 520
Almost All Antipsychotics Result in Weight Gain: A Meta-Analysis
Bak, M., Fransen, A., Janssen, J., van Os, J., & Drukker, M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0094112 · Cited by 490 · cited 2×
“An interesting finding described by Bak et al was that weight increased more significantly during the period beyond 38 weeks than within the first 6 weeks for olanzapine and FGA group and for olanzapine alone in antipsychoticnaïve group.(13) Factors associated with rapid weight gain in the initial period were younger…”
BackgroundMethodObesity as a risk factor for antipsychotic noncompliance
Weiden, P. J., Mackell, J. A., & McDonnell, D. D. (2004) · Schizophrenia Research · doi:10.1016/s0920-9964(02)00498-x · Cited by 433
Wu, R.-R., Zhao, J.-P., Jin, H., Shao, P., Fang, M.-S., Guo, X.-F., He, Y.-Q., Liu, Y.-J., Chen, J.-D., & Li, L.-H. (2008) · JAMA · doi:10.1001/jama.2007.56-b · Cited by 366
De Hert, M., Dobbelaere, M., Sheridan, E. M., Cohen, D., & Correll, C. U. (2011) · European Psychiatry · doi:10.1016/j.eurpsy.2010.09.011 · Cited by 362
Wulffelé, M. G., Kooy, A., de Zeeuw, D., Stehouwer, C. D. A., & Gansevoort, R. T. (2004) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01328.x · Cited by 359
Mitchell, A. J., Vancampfort, D., De Herdt, A., Yu, W., & De Hert, M. (2013) · Schizophrenia Bulletin · doi:10.1093/schbul/sbs082 · Cited by 327
Lee, A., & Morley, J. E. (1998) · Obesity Research · doi:10.1002/j.1550-8528.1998.tb00314.x · Cited by 320 · cited 1×
“The main mechanism of weight loss may be by reduction of insulin resistance and suppression of appetite.(60) Increased level of glucagon-like peptide-1 (GLP-1) may contribute.”
BackgroundÁlvarez-Jiménez, M., Hetrick, S. E., González-Blanch, C., Gleeson, J. F., & McGorry, P. D. (2008) · British Journal of Psychiatry · doi:10.1192/bjp.bp.107.042853 · Cited by 317
Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia.
Kinon, B. J., Basson, B. R., Gilmore, J. A., & Tollefson, G. D. (2001) · PubMed · Cited by 317
Cooper, S. J., Reynolds, G. P., order):, W. E. C.-A. (. A., Barnes, T., England, E., Haddad, P., Heald, A., Holt, R., Lingford-Hughes, A., Osborn, D., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116645254 · Cited by 292 · cited 1×
“These interventions are often referred to as “behavioral lifestyle programs”.(53) Both individual interventions and group interventions have been studied.”
BackgroundHenderson, D. C., Vincenzi, B., Andrea, N. V., Ulloa, M., & Copeland, P. M. (2015) · The Lancet Psychiatry · doi:10.1016/s2215-0366(15)00115-7 · Cited by 288 · cited 1×
“The differential effects on weight have been explained by the differing affinity of medications at these receptors.(16,17) Antipsychotics affect neuropeptides associated with appetite control and energy metabolism.”
BackgroundAmantadine Inhibits NMDA Receptors by Accelerating Channel Closure during Channel Block
Blanpied, T. A., Clarke, R. J., & Johnson, J. W. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.4262-04.2005 · Cited by 251
RATZONI, G., GOTHELF, D., BRAND-GOTHELF, A., REIDMAN, J., KIKINZON, L., GAL, G., PHILLIP, M., APTER, A., & WEIZMAN, R. (2002) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200203000-00014 · Cited by 237
Interventions to reduce weight gain in schizophrenia
Faulkner, G., Cohn, T., & Remington, G. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005148.pub2 · Cited by 222
Mizuno, Y., Suzuki, T., Nakagawa, A., Yoshida, K., Mimura, M., Fleischhacker, W. W., & Uchida, H. (2014) · Schizophrenia Bulletin · doi:10.1093/schbul/sbu030 · Cited by 202
Warkentin, L. M., Das, D., Majumdar, S. R., Johnson, J. A., & Padwal, R. S. (2014) · Obesity Reviews · doi:10.1111/obr.12113 · Cited by 198
Fleischhacker, W. W., Heikkinen, M. E., Olié, J.-P., Landsberg, W., Dewaele, P., McQuade, R. D., Loze, J.-Y., Hennicken, D., & Kerselaers, W. (2010) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145710000490 · Cited by 198
Adherence to antipsychotic medications.
Perkins, D. O. (1999) · PubMed · Cited by 193
Stroup, T. S., McEvoy, J. P., Ring, K. D., Hamer, R. H., LaVange, L. M., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Nussbaum, A. M., Lieberman, J. A., et al. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10111609 · Cited by 193
Pringsheim, T., Panagiotopoulos, C., Davidson, J., Ho, J., & The Canadian Alliance for Monitoring Effectiveness and Safety of Antipsychotics in Children (CAMESA) guideline group (2011) · Paediatrics & Child Health · doi:10.1093/pch/16.9.581 · Cited by 192
Trends in the Use of Typical and Atypical Antipsychotics in Children and Adolescents
Patel, N. C., Crismon, M. L., Hoagwood, K., Johnsrud, M. T., Rascati, K. L., Wilson, J. P., & Jensen, P. S. (2005) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000157543.74509.c8 · Cited by 186
Zhang, J.-P., Lencz, T., Zhang, R. X., Nitta, M., Maayan, L., John, M., Robinson, D. G., Fleischhacker, W. W., Kahn, R. S., Ophoff, R. A., et al. (2016) · Schizophrenia Bulletin · doi:10.1093/schbul/sbw058 · Cited by 181
Álvarez-Jiménez, M., González-Blanch, C., Vázquez-Barquero, J. L., Pérez-Iglesias, R., Martínez-García, O., Pérez-Pardal, T., Ramírez-Bonilla, M. L., & Crespo-Facorro, B. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n0812 · Cited by 180
Tek, C., Kucukgoncu, S., Guloksuz, S., Woods, S. W., Srihari, V. H., & Annamalai, A. (2016) · Early Intervention in Psychiatry · doi:10.1111/eip.12251 · Cited by 173
Schizophrenia and the risk of cardiovascular diseases: A meta-analysis of thirteen cohort studies
Fan, Z., Wu, Y., Shen, J. F., Ji, T., & Zhan, R. (2013) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2013.07.011 · Cited by 171
Atypical Antipsychotic-Induced Weight Gain: Insights into Mechanisms of Action
Roerig, J. L., Steffen, K. J., & Mitchell, J. E. (2011) · CNS Drugs · doi:10.2165/11596300-000000000-00000 · Cited by 166
De Hert, M., Yu, W., Detraux, J., Sweers, K., van Winkel, R., & Correll, C. U. (2012) · CNS Drugs · doi:10.2165/11634500-000000000-00000 · Cited by 161
Predictors of medication adherence in patients with schizophrenia and bipolar disorder
Jónsdóttir, H., Opjordsmoen, S., Birkenaes, A. B., Simonsen, C., Engh, J. A., Ringen, P. A., Vaskinn, A., Friis, S., Sundet, K. S., & Andreassen, O. A. (2012) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2012.01911.x · Cited by 159
Evans, S. M., Newton, R., & Higgins, S. (2005) · Australian & New Zealand Journal of Psychiatry · doi:10.1080/j.1440-1614.2005.01607.x · Cited by 156
Lasikiewicz, N., Myrissa, K., Hoyland, A., & Lawton, C. L. (2014) · Appetite · doi:10.1016/j.appet.2013.09.017 · Cited by 144 · cited 1×
“A meta-analysis of 36 studies of behavioral or dietary interventions for obesity reported improvement in body image and health-related quality of life following weight loss.(45) However, another meta-analysis found no significant improvement in mental health or overall healthrelated quality of life after weight loss,…”
BackgroundThe CATIE Schizophrenia Trial: Results, Impact, Controversy
Manschreck, T. C., & Boshes, R. A. (2007) · Harvard Review of Psychiatry · doi:10.1080/10673220701679838 · Cited by 138
Poyurovsky, M., Isaacs, I., Fuchs, C., Schneidman, M., Faragian, S., Weizman, R., & Weizman, A. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.2.297 · Cited by 136
Bruins, J., Jörg, F., Bruggeman, R., Slooff, C., Corpeleijn, E., & Pijnenborg, M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0112276 · Cited by 129 · cited 1×
“There was no significant effect on blood pressure or cholesterol.(55) An RCT comparing an early behavioral intervention with routine care in preventing AIWG in drug-naive first-episode psychosis patients found that the behavioral intervention group gained significantly less weight (mean =4.”
BackgroundHosojima, H., Togo, T., Odawara, T., Hasegawa, K., Miura, S., Kato, Y., Kanai, A., Kase, A., Uchikado, H., & Hirayasu, Y. (2005) · Journal of Psychopharmacology · doi:10.1177/0269881105056647 · Cited by 128
Fakhoury, W. K. H., Wright, D., & Wallace, M. (2001) · International Clinical Psychopharmacology · doi:10.1097/00004850-200105000-00004 · Cited by 127
A Double-Blind, Placebo-Controlled Trial of Sibutramine for Olanzapine-Associated Weight Gain
Henderson, D. C., Copeland, P. M., Daley, T. B., Borba, C. P. C., Cather, C., Nguyen, D. D., Louie, P. M., Evins, A. E., Freudenreich, O., Hayden, D. L., et al. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.5.954 · Cited by 126
Mukundan, A., Faulkner, G., Cohn, T. A., & Remington, G. J. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006629.pub2 · Cited by 124
Views of Young People in Early Intervention Services for First-Episode Psychosis in England
Lester, H. E., Marshall, M., Jones, P. B., Fowler, D. G., Amos, T., Khan, N., & Birchwood, M. J. (2011) · Psychiatric Services · doi:10.1176/appi.ps.62.8.882 · Cited by 113
Ko, Y., Joe, S.-H., Jung, I., & Kim, S. (2005) · Clinical Neuropharmacology · doi:10.1097/01.wnf.0000172994.56028.c3 · Cited by 106
Pathak, P., West, D., Martin, B. C., Helm, M. E., & Henderson, C. (2010) · Psychiatric Services · doi:10.1176/ps.2010.61.2.123 · Cited by 106
Vandenberghe, F., Gholam‐Rezaee, M., Saigí-Morgui, N., Delacrétaz, A., Choong, E., Solida-Tozzi, A., Kolly, S., Thonney, J., Gallo, S. F., Hedjal, A., et al. (2015) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14m09358 · Cited by 106
Antipsychotics-induced metabolic alterations: Focus on adipose tissue and molecular mechanisms
Gonçalves, P., Araújo, J. R., & Martel, F. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2014.11.008 · Cited by 105
Afshar, H., Roohafza, H., Mousavi, S. G., Golchin, S., Toghianifar, N., Sadeghi, M., & Talaei, M. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108089816 · Cited by 95
Nizatidine for prevention of weight gain with olanzapine: a double-blind placebo-controlled trial
Cavazzoni, P. A., Tanaka, Y., Roychowdhury, S. M., Breier, A., & Allison, D. B. (2003) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(02)00127-x · Cited by 94
Interventions to Reduce Weight Gain in Schizophrenia
Faulkner, G., Cohn, T. A., & Remington, G. J. (2007) · Schizophrenia Bulletin · doi:10.1093/schbul/sbm022 · Cited by 93
Graham, K. A., Gu, H., Lieberman, J. A., Harp, J. B., & Perkins, D. O. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.9.1744 · Cited by 92 · cited 1×
“76 Another trial showed that amantadine 100–300 mg was effective in attenuating or promoting weight loss in patients who had olanzapine-induced weight gain.”
BackgroundFiedorowicz, J. G., Miller, D. D., Bishop, J. R., Calarge, C. A., Ellingrod, V. L., & Haynes, W. G. (2012) · Current Psychiatry Reviews · doi:10.2174/157340012798994867 · Cited by 87
Amantadine for weight gain associated with olanzapine treatment
Deberdt, W. G., Winokur, A., Cavazzoni, P. A., Trzaskoma, Q., Carlson, C. D., Bymaster, F. P., Wiener, K., Floris, M., & Breier, A. F. (2004) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2004.03.005 · Cited by 86
Poyurovsky, M., Fuchs, C., Pashinian, A., Levi, A., Faragian, S., Maayan, R., & Gil‐Ad, I. (2007) · Psychopharmacology · doi:10.1007/s00213-007-0731-1 · Cited by 82
Stahl, S. M., Cucchiaro, J. B., Simonelli, D., Hsu, J., Pikalov, A., & Loebel, A. D. (2013) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.12m08084 · Cited by 74
Poyurovsky, M., Fuchs, C., Pashinian, A., Levi, A., Weizman, R., & Weizman, A. (2012) · Psychopharmacology · doi:10.1007/s00213-012-2935-2 · Cited by 74
Kristiana, I., Sharpe, L. J., Catts, V. S., Lutze-Mann, L. H., & Brown, A. J. (2009) · The Pharmacogenomics Journal · doi:10.1038/tpj.2009.62 · Cited by 70
Lian, J., Huang, X., Pai, N. B., & Deng, C. (2014) · PLoS ONE · doi:10.1371/journal.pone.0104160 · Cited by 69
Baptista, T., Uzcátegui, E., Rangel, N., Fakih, Y. E., Galeazzi, T., Beaulieu, S., & de Baptista, E. A. (2008) · Psychiatry Research · doi:10.1016/j.psychres.2008.01.011 · Cited by 64
Atmaca, M., Kuloğlu, M., Tezcan, E., & Üstündağ, B. (2003) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.514 · Cited by 62
Goodall, E., Oxtoby, C., Richards, R. P., Watkinson, G., Brown, D., & Silversonte, T. (1988) · The British Journal of Psychiatry · doi:10.1192/bjp.153.2.208 · Cited by 61
A double‐blind, placebo‐controlled trial of sibutramine for clozapine‐associated weight gain
Henderson, D. C., Fan, X., Copeland, P. M., Borba, C. P. C., Daley, T. B., Nguyen, D. D., Zhang, H., Hayden, D. L., Freudenreich, O., Cather, C., et al. (2006) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2006.00855.x · Cited by 61
Ameliorating antipsychotic-induced weight gain by betahistine: Mechanisms and clinical implications
Lian, J., Huang, X., Pai, N. B., & Deng, C. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.02.011 · Cited by 61
Lu, M., Wang, T., Lin, T., Shao, W., Chang, S.-H., Chou, J., Ho, Y.-F., Liao, Y., & Chen, V. C. (2014) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2014.12.001 · Cited by 60
Grandy, S., Fox, K. M., & Hardy, E. (2013) · Current Therapeutic Research · doi:10.1016/j.curtheres.2013.06.004 · Cited by 58
Lykkegaard, K., Larsen, P. J., Vrang, N., Bock, C., Bock, T. G., & Knudsen, L. B. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.05.011 · Cited by 57
Influence of Topiramate on Olanzapine-Related Adiposity in Women
Nickel, M. K., Nickel, C., Muehlbacher, M., Leiberich, P. K., Kaplan, P., Lahmann, C., Tritt, K., Krawczyk, J., Kettler, C., Egger, C., et al. (2005) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000162806.46453.38 · Cited by 53
Apovian, C. M. (2008) · Yearbook of Endocrinology · doi:10.1016/s0084-3741(08)79231-x · Cited by 52
Mifepristone treatment of olanzapine-induced weight gain in healthy men
Gross, C., Blasey, C. M., Roe, R. L., Allen, K., Block, T. S., & Belanoff, J. K. (2009) · Advances in Therapy · doi:10.1007/s12325-009-0070-1 · Cited by 47
Assunção, S. S., Ruschel, S. I., Rosa, L. D. C. R., Campos, J. A. O., Alves, M. J. O., Bracco, O. L., & de Lima, M. S. (2006) · Brazilian Journal of Psychiatry · doi:10.1590/s1516-44462006005000007 · Cited by 39
Betahistine decreases olanzapine-induced weight gain and somnolence in humans
Barak, N., Beck, Y., & Albeck, J. H. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881115626349 · Cited by 39
Bessesen, D. H. (2007) · Yearbook of Endocrinology · doi:10.1016/s0084-3741(08)70087-8 · Cited by 38
Wulffelé, M. G., Kooy, A., de Zeeuw, D., Stehouwer, C. D. A., & Gansevoort, R. T. (2002) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2002.161311.x · Cited by 33
Ball, M. P., Warren, K. R., Feldman, S. M., McMahon, R. P., Kelly, D. L., & Buchanan, R. (2011) · Clinical Schizophrenia & Related Psychoses · doi:10.3371/csrp.5.1.3 · Cited by 33
Barak, N., Beck, Y., & Albeck, J. H. (2016) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000489 · Cited by 33
Eapen, V., & John, G. (2011) · Australasian Psychiatry · doi:10.3109/10398562.2010.539609 · Cited by 32
de Silva, V. A., Dayabandara, M., Wijesundara, H., Henegama, T., Gunewardena, H., Suraweera, C. U., & Hanwella, R. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115613519 · Cited by 32
Self-citationAntipsychotic Cardiometabolic Side Effect Monitoring in a State Community Mental Health System
Cotes, R. O., de Nesnera, A., Kelly, M., Orsini, K., Xie, H., McHugo, G. J., Bartels, S. J., & Brunette, M. F. (2015) · Community Mental Health Journal · doi:10.1007/s10597-015-9833-0 · Cited by 31
Constans, J. (2006) · Journal des Maladies Vasculaires · doi:10.1016/s0398-0499(06)76549-0 · Cited by 30
Barak, Y., & Aizenberg, D. (2010) · Journal of Obesity · doi:10.1155/2011/898013 · Cited by 27
Ghanizadeh, A. J., Nikseresht, M. S., & Sahraian, A. (2013) · Schizophrenia Research · doi:10.1016/j.schres.2013.03.021 · Cited by 24
Ak, M., Sezlev, D., Sütçigil, L., Akarsu, S., Özgen, F., & Yanık, T. (2012) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2012.06.012 · Cited by 23
Henderson, D. C., Freudenreich, O., Borba, C. P. C., Wang, X., Copeland, P. M., Macklin, E. A., Fan, X., Cather, C., & GOFF, D. C. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2011.04.009 · Cited by 22
Roerig, J. L., Steffen, K. J., Mitchell, J. E., Crosby, R. D., & Gosnell, B. A. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.10.037 · Cited by 21
Evers, S. S., van Vliet, A., van Vugt, B., Scheurink, A. J. W., & van Dijk, G. (2016) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2015.12.024 · Cited by 16
Community Adherence to Schizophrenia Treatment and Safety Monitoring Guidelines
Keller, W. R., Fischer, B. A., McMahon, R. P., Meyer, W. A., Blake, M., & Buchanan, R. W. (2013) · The Journal of Nervous and Mental Disease · doi:10.1097/nmd.0000000000000093 · Cited by 13
Weissman, E. M., Jackson, C. T., Schooler, N. R., Goetz, R. R., & Essock, S. M. (2011) · Clinical Schizophrenia & Related Psychoses · doi:10.3371/csrp.5.4.4 · Cited by 11
Cited by
Obesity in children and adolescents: epidemiology, causes, assessment, and management
Jebeile, H., Kelly, A. S., O'Malley, G., & Baur, L. A. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00047-x · Cited by 1,099
Wiss, D. A., & Brewerton, T. D. (2020) · Physiology & Behavior · doi:10.1016/j.physbeh.2020.112964 · Cited by 273
Masood, B., & Moorthy, M. (2023) · Clinical Medicine · doi:10.7861/clinmed.2023-0168 · Cited by 252
The Burden of Antipsychotic-Induced Weight Gain and Metabolic Syndrome in Children
Libowitz, M. R., & Nurmi, E. L. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.623681 · Cited by 99
Gilbert, O., Gulati, M., Gluckman, T. J., Kittleson, M. M., Rikhi, R., Saseen, J. J., & Tchang, B. G. (2025) · JACC · doi:10.1016/j.jacc.2025.05.024 · Cited by 65
Metadata
- Authors
- Dayabandara, M., Hanwella, R., Ratnatunga, S., Seneviratne, S., Suraweera, C., & de Silva, V.
- Venue
- Neuropsychiatric Disease and Treatment
- Publisher
- Informa UK Limited
- Published
- 2017-08
- Volume
- Volume 13
- Pages
- 2231-2241
- ISSN
- 1176-6328 (ISSN-L)
- 1178-2021
- OpenAlex
- W2746379998
- Cited by
- 367
- References
- 97
- FWCI
- 15.94
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.